EUVIMEDEUVIMED entdecken
BeobachtungsstudieValidierungsstudieOpen Access · CC BY 4.0

Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma

Claudia Moneta iD, Matteo Trevisan iD, Carla Colombo iD, Alessia De Luca, Marina Lugaresi iD, Giacomo Maria Reali, Giacomo Gazzano iD, Luca Persani iD, Laura Fugazzola iD, Simone De Leo iD

The Journal of Clinical Endocrinology & Metabolism · 16.09.2026 · 111 (10) · 2883-2889

DOI: 10.1210/clinem/dgag167 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 17.04.2026. Verfasst von Claudia Moneta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Milan, Milan 20142, Italy. Hauptthemen laut MEDLINE: Practice Guidelines as Topic, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting.

Design

Retrospective observational study.

Setting

Tertiary care center. Patients Data from 670 PTC patients with complete histopathological and final disease outcome were included. Main Outcome measures We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction.

Results

The reclassification according to the 2025 ATA risk stratification showed that the proportion of “low-risk” PTC decreased by 22.2%, while “intermediate-risk” and “high-risk” PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the 2 stratification systems revealed that structural disease persistence in the 2025 “low-risk” and “high-risk” classes was comparable. The 2025 “intermediate-high-risk” class was similar to the former “intermediate-risk” class, whereas the “low-intermediate-risk” class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 “low-risk” class (P = .003), but lower than that of the 2015 “intermediate-risk” class (P = .012).

Conclusion

In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined “low-intermediate-risk” class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior “low-risk” and “intermediate-risk” classes, highlighting the need for dedicated prospective studies to address proper management of this newly defined group of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Guidelines as TopicThyroid Cancer, PapillaryThyroid NeoplasmsAdultFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk Factors

Stichwörter der Autor:innen

ATA risk stratificationAmerican Thyroid Associationdisease outcomepapillary thyroid cancerrisk factorsstructural recurrence or persistence

Autor:innen und Institutionen

  • Department of Health Sciences, University of Milan, Milan 20142, Italy.
  • Department of Endocrinology, ASST Santi Paolo e Carlo, Milan 20142, Italy.
  • Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan 20145, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, Milan 20122, Italy.
  • Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan 20133, Italy.
  • Pathology Unit, IRCCS Istituto Auxologico Italiano, Milan 20145, Italy.

ORCID-Profile: Claudia Moneta, Matteo Trevisan, Carla Colombo, Marina Lugaresi, Giacomo Gazzano, Luca Persani, Laura Fugazzola, Simone De Leo

Förderung

  • Ministero della Salute

Zitieren

APA

Moneta, C., Trevisan, M., Colombo, C., De Luca, A., Lugaresi, M., Reali, G. M., Gazzano, G., Persani, L., Fugazzola, L., & De Leo, S. (2026). Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 111(10), 2883-2889. https://doi.org/10.1210/clinem/dgag167

Vancouver

Moneta C, Trevisan M, Colombo C, De Luca A, Lugaresi M, Reali GM, et al. Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2026;111(10):2883-2889. doi:10.1210/clinem/dgag167

BibTeX
@article{Moneta2026,
  author = {Moneta, Claudia and Trevisan, Matteo and Colombo, Carla and De Luca, Alessia and Lugaresi, Marina and Reali, Giacomo Maria and Gazzano, Giacomo and Persani, Luca and Fugazzola, Laura and De Leo, Simone},
  title = {Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {10},
  pages = {2883--2889},
  doi = {10.1210/clinem/dgag167}
}
Kostenlos starten →